Program
eptinezumab
Also written as “Eptinezumab”, “ALD403” and “ALD403 (Eptinezumab)”.
Its studies are mostly in Migraine Disorders · Cluster Headache, led by 2 companies.
Drug pageEptinezumab: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeckits history only | 223 open or running | phase 4since Feb 23, 2022 | Apr 16, 2012 | Mar 26, 2027phase 3 · NCT04965675 |
| Dr George Medvedev | 11 open or running | phase 3since May 16, 2024 | May 16, 2024 | Mar 2028phase 3 · NCT06428838 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dr George Medvedev only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2016Named eptinezumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ALD403
- May 16, 2024First study: phase 3 study in Migraine DisordersFirst studyNCT06428838 · 102 planned · Canada
Ahead
- Mar 2028Primary completion: phase 3 study in Migraine DisordersNCT06428838
TargetBeta
“Calcitonin gene-related peptide inhibitor”ChEMBL 37, by rule
Studies
The one study Dr George Medvedev leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06428838Migraine Disorders · Canada | 3 | By invitation | Mar 2028 | 102 |
How it is read
Names in the registry
- “Eptinezumab”, 17 entries
- “ALD403”, 5 entries
- “ALD403 (Eptinezumab)”, 2 entries
Conditions, from the studies’ own filings
- Migraine Disorders, 19 studies
- Cluster Headache, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.